Portage Biotech (NASDAQ:ALP) Raised to “Hold” at Zacks Research

Portage Biotech (NASDAQ:ALP) was upgraded by investment analysts at Zacks Research to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.

A number of other equities analysts also recently issued reports on the company. HC Wainwright started coverage on Portage Biotech in a report on Monday. They issued a “neutral” rating and a $0.25 price objective for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Portage Biotech in a report on Friday, July 24th. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Portage Biotech has an average rating of “Reduce” and an average price target of $0.25.

Portage Biotech Stock Down 7.1%

ALP stock opened at $0.15 on Tuesday. Portage Biotech has a fifty-two week low of $0.14 and a fifty-two week high of $13.80. The business’s 50 day moving average price is $0.28 and its two-hundred day moving average price is $0.34. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.31 and a current ratio of 0.31. The company has a market capitalization of $3.54 million, a price-to-earnings ratio of -0.02 and a beta of 0.61.

Portage Biotech (NASDAQ:ALP) last announced its earnings results on Thursday, July 16th. The company reported $0.48 earnings per share (EPS) for the quarter. The firm had revenue of $0.05 million during the quarter. As a group, analysts forecast that Portage Biotech will post -0.28 earnings per share for the current fiscal year.

Trending Headlines about Portage Biotech

Here are the key news stories impacting Portage Biotech this week:

• Positive Sentiment: HC Wainwright’s $0.25 price target is above Portage Biotech’s recent trading level, suggesting meaningful theoretical upside if the company executes on its development plans. The firm also expects losses to narrow from an estimated $(0.28) per share in fiscal 2027 to $(0.17) in fiscal 2028.
• Neutral Sentiment: HC Wainwright forecasts quarterly losses of $(0.10), $(0.07), $(0.07), and $(0.06) per share for fiscal 2027, resulting in a $(0.28) full-year loss. For fiscal 2028, the analyst projects a relatively consistent $(0.04) quarterly loss and a $(0.17) annual loss, indicating gradual improvement but no expected profitability in the forecast period. Portage Biotech analyst estimates
• Negative Sentiment: The Neutral rating and continuing projected losses may limit investor enthusiasm. Portage Biotech has also experienced substantial share-price weakness, trading close to its one-year low, while its latest reported quarterly revenue was only $0.05 million.

Portage Biotech Company Profile

Portage Biotech (NASDAQ:ATON) is a biotechnology company focused on acquiring, developing and advancing therapeutic candidates and platform technologies. The company concentrates its development efforts primarily in areas such as oncology, immunology/inflammation and infectious disease, seeking to move programs from discovery and preclinical stages into clinical development through subsidiary companies and collaborative arrangements.

Portage structures its operations to support a diversified pipeline, advancing both small molecules and biologics by funding preclinical research, conducting clinical trials, and managing regulatory interactions.